Patents Assigned to Genentech
  • Publication number: 20190071511
    Abstract: The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.
    Type: Application
    Filed: February 26, 2018
    Publication date: March 7, 2019
    Applicant: Genentech, Inc.
    Inventors: Camellia W. ADAMS, Andrew C. CHAN, Craig W. CROWLEY, Henry B. LOWMAN, Gerald R. NAKAMURA, Leonard G. PRESTA
  • Publication number: 20190071516
    Abstract: The present invention concerns dosages for treatment of human cancer patients with an anti-Epidermal Growth Factor Receptor (EGFR) antibody.
    Type: Application
    Filed: November 12, 2018
    Publication date: March 7, 2019
    Applicant: Genentech, Inc.
    Inventors: Sharon A. Baughman, Steven Shak
  • Publication number: 20190062432
    Abstract: The invention provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: July 24, 2018
    Publication date: February 28, 2019
    Applicant: Genentech, Inc.
    Inventors: Steven R. Leong, Andrew Polson, Paul Polakis, Yan Wu, Wei-Ching Liang, Ron Firestein
  • Publication number: 20190062444
    Abstract: The invention provides compositions and methods for treating cancers. The method comprises administering an anti-angiogenesis agent and an OX40 binding agonist.
    Type: Application
    Filed: June 28, 2018
    Publication date: February 28, 2019
    Applicant: Genentech, Inc.
    Inventors: Kevin Walsh, Patricia De Almeida, Changchun Du, Jeong Kim, Jing Zhu, Jack Bevers, III, James Andya, Ye Shen
  • Patent number: 10214514
    Abstract: The present invention provides compounds which antagonize hedgehog signaling and inhibit HDAC activity. The compounds can be used in methods of treating proliferative diseases and disorders such as cancer.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: February 26, 2019
    Assignees: Curis, Inc., Genentech, Inc.
    Inventors: Xiong Cai, Changgeng Qian, Haixiao Zhai
  • Publication number: 20190054102
    Abstract: The invention provides antibody-drug conjugates comprising an antibody conjugated to an anthracycline drug moiety via a disulfide linker, anthracycline disulfide intermediates, and methods of using the antibody-drug conjugates.
    Type: Application
    Filed: November 1, 2018
    Publication date: February 21, 2019
    Applicant: Genentech, Inc.
    Inventors: John A. Flygare, Thomas H. Pillow
  • Publication number: 20190055317
    Abstract: The present invention concerns dosages for treatment of human cancer patients with an anti-Epidermal Growth Factor Receptor (EGFR) antibody.
    Type: Application
    Filed: October 29, 2018
    Publication date: February 21, 2019
    Applicant: Genentech, Inc.
    Inventors: Sharon A. Baughman, Steven Shak
  • Publication number: 20190054138
    Abstract: The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by regulating binding of HGF ? chain to c-met.
    Type: Application
    Filed: March 15, 2018
    Publication date: February 21, 2019
    Applicant: Genentech, Inc.
    Inventors: Daniel K. Kirchhofer, Robert A. Lazarus, Xiaoyi Yao
  • Publication number: 20190056399
    Abstract: The present invention provides methods for producing disulfide oxidoreductase A (DsbA) and disulfide oxidoreductase C (DsbC) polypeptides at very high levels of purity. Also provided are ultrapure DsbA and DsbC and methods of using same, e.g., for use in immunoassays to show removal of DsbA and DsbC from biologics produced in bacteria.
    Type: Application
    Filed: July 24, 2018
    Publication date: February 21, 2019
    Applicant: Genentech, Inc.
    Inventors: Marc Wong, Liliana T. Yee, Amy Lim, Chris B. Fong
  • Patent number: 10208120
    Abstract: The invention provides dual specific anti-FGFR2 and FGFR3 (FGFR2/3) antibodies, and compositions comprising and methods of using these antibodies.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: February 19, 2019
    Assignee: GENENTECH, INC.
    Inventors: Yiyuan Yin, Avi Ashkenazi, Paul J. Carter, Mark Chen, Junichiro Sonoda
  • Patent number: 10208355
    Abstract: The invention provides methods and compositions to detect expression of one or more biomarkers for identifying and treating patients having glioblastomas who are likely to be responsive to VEGF antagonist therapy. The invention also provides kits and articles of manufacture for use in the methods.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: February 19, 2019
    Assignee: Genentech, Inc.
    Inventors: Carlos Bais, Richard Bourgon, Thomas Sandmann
  • Patent number: 10206931
    Abstract: The present invention relates to compounds of formula (I): and to salts thereof, wherein A has any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: February 19, 2019
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: F. Anthony Romero, Steven R. Magnuson, Richard Pastor, Vickie Hsiao-Wei Tsui, Jeremy Murray, Terry Crawford, Daniel J. Burdick, Brian K. Albrecht, Alexandre Cote, Alexander M. Taylor, Christopher G. Nasveschuck, Yves LeBlanc, Michael Charles Hewitt, Kwong Wah Lai, Kevin Chen
  • Patent number: 10202378
    Abstract: The present invention relates to compounds of formula (I): and to salts thereof, wherein R1-R6 have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of TAF1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various TAF1-mediated disorders.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: February 12, 2019
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Marc Adler, Daniel J. Burdick, Terry Crawford, Martin Duplessis, Steven R. Magnuson, Christopher G. Nasveschuk, F. Anthony Romero, Yong Tang, Vickie Hsiao-Wei Tsui, Shumei Wang
  • Patent number: 10202354
    Abstract: The present invention relates to compounds useful as inhibitors of one or more histone demethylses, such as KDM2b. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: February 12, 2019
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Brian K. Albrecht, Alexandre Cote, Victor Gehling, Vickie Hsiao-Wei Tsui, James Richard Jr. Kiefer, Jun Liang, Steven Magnuson, Christopher G. Nasveschuk, F. Anthony Romero, Alexander M. Taylor
  • Publication number: 20190040142
    Abstract: The presently disclosed subject matter relates to multispecific antibodies, e.g., bispecific antibodies and biepitopic antibodies, and methods for screening for such antibodies, and a novel antibody structure that can be used to screen for such bispecific antibodies and biepitopic antibodies.
    Type: Application
    Filed: May 8, 2018
    Publication date: February 7, 2019
    Applicant: GENENTECH, INC.
    Inventors: Diana Ronai Dunshee, Joanne Hongo, Hok Seon Kim, Junichiro Sonoda, Christoph Spiess, Angie Grace Yee
  • Patent number: 10196454
    Abstract: The invention provides anti-PMEL17 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: February 5, 2019
    Assignee: Genentech, Inc.
    Inventors: Youjun Chen, William Mallet, Paul Polakis, Christine Tan, Jyoti Asundi, Suzanna Clark
  • Publication number: 20190031746
    Abstract: The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease.
    Type: Application
    Filed: February 22, 2018
    Publication date: January 31, 2019
    Applicants: AC Immune S.A., Genentech, Inc.
    Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
  • Publication number: 20190031607
    Abstract: The invention provides compounds having the general Formula (I); and pharmaceutically acceptable salts thereof; wherein the variables RA, RAA, subscript n, subscript q, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, D and E have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: October 2, 2018
    Publication date: January 31, 2019
    Applicants: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Jean-Christophe ANDREZ, Philippe BERGERON, Paul Robert BICHLER, Sultan CHOWDHURY, Christoph Martin DEHNHARDT, Thilo FOCKEN, Wei GONG, Michael Edward GRIMWOOD, Abid HASAN, Ivan William HEMEON, Qi JIA, Brian Salvatore SAFINA, Shaoyi SUN, Michael Scott WILSON, Alla Yurevna ZENOVA
  • Publication number: 20190030160
    Abstract: The present invention relates to compositions and methods for improving the safety of blood-brain barrier receptor-mediated blood-brain barrier transport.
    Type: Application
    Filed: July 12, 2018
    Publication date: January 31, 2019
    Applicant: Genentech, Inc.
    Inventors: Ryan Jefferson Watts, Joy Yu Zuchero, Jessica Couch, Mark Dennis
  • Patent number: RE47223
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: February 5, 2019
    Assignee: GENENTECH, INC.
    Inventors: Mark S. Dennis, Paul Polakis, William Mallet